Aptose Biosciences Inc.
APS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -25.43M | -35.80M | -40.29M | -47.17M | -51.21M |
| Total Depreciation and Amortization | 404.00K | 417.00K | 432.00K | 444.00K | 466.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | 50.00K | 50.00K |
| Total Other Non-Cash Items | 532.00K | 1.62M | 2.20M | 2.69M | 3.74M |
| Change in Net Operating Assets | -11.48M | -3.41M | 330.00K | -1.08M | 2.36M |
| Cash from Operations | -35.98M | -37.18M | -37.34M | -45.06M | -44.60M |
| Capital Expenditure | -5.00K | 0.00 | 0.00 | -29.00K | -29.00K |
| Sale of Property, Plant, and Equipment | 23.00K | 18.00K | 18.00K | 1.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 1.94M | 14.89M | 10.97M | 10.00M |
| Cash from Investing | 18.00K | 1.96M | 14.91M | 10.94M | 9.97M |
| Total Debt Issued | 10.00M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 26.79M | 27.63M | 22.53M | 18.71M | 6.91M |
| Repurchase of Common Stock | -3.35M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -21.00K | -167.00K | -172.00K | 0.00 | 0.00 |
| Cash from Financing | 33.41M | 27.46M | 22.36M | 18.71M | 6.91M |
| Foreign Exchange rate Adjustments | 0.00 | -1.00K | 0.00 | -2.00K | 1.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.55M | -7.76M | -70.00K | -15.42M | -27.72M |